According to SurgePays's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.66667. At the end of 2022 the company had a P/E ratio of -131.
Year | P/E ratio | Change |
---|---|---|
2022 | -131 | 19367.62% |
2021 | -0.6739 | -43.8% |
2020 | -1.20 | -64.02% |
2019 | -3.33 | -91.67% |
2018 | -40.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.0 | 134.71% | ๐บ๐ธ USA |
Novartis NVS | 27.5 | 488.37% | ๐จ๐ญ Switzerland |
Stryker Corporation SYK | 49.0 | 950.91% | ๐บ๐ธ USA |
Cooper Companies COO | 17.6 | 276.60% | ๐บ๐ธ USA |
STAAR Surgical STAA | 101 | 2,074.48% | ๐บ๐ธ USA |
CONMED CNMD | 39.7 | 751.50% | ๐บ๐ธ USA |
Integra LifeSciences IART | 22.5 | 382.85% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.